WNK (lysine deficient protein kinase 1), also known as WNK1, is an enzyme that is encoded by the WNK1 gene. [5] [6] [7] [8] [9] WNK1 is serine-threonine protein kinase and part of the "with no lysine/K" kinase WNK family. [5] [6] [7] [9] The predominant role of WNK1 is the regulation of cation-Cl− cotransporters (CCCs) such as the sodium chloride cotransporter ( NCC), basolateral Na-K-Cl symporter ( NKCC1), and potassium chloride cotransporter (KCC1) located within the kidney. [5] [6] [9] CCCs mediate ion homeostasis and modulate blood pressure by transporting ions in and out of the cell. [5] WNK1 mutations as a result have been implicated in blood pressure disorders/diseases; a prime example being familial hyperkalemic hypertension (FHHt). [5] [6] [7] [8] [9]
The WNK1 protein is composed of 2382 amino acids (molecular weight 230 kDa). [8] The protein contains a kinase domain located within its short N-terminal domain and a long C-terminal tail. [8] The kinase domain has some similarity to the MEKK protein kinase family. [8] As a member of the WNK family, the kinase's catalytic lysine residue is uniquely located in beta strand 2 of the glycine loop. [8] In order to have kinase activity, WNK1 must autophosphorylate the serine 382 residue found in its activation loop. [8] [5] Further, phosphorylation at another site (Ser378) increases WNK1 activity. [5] An autoinhibitory domain is located within the C-terminal domain along with a HQ domain that is needed for WNK1 interactions with other WNKs. [5] [6] [7] [8] The interactions between WNKs play an important role in function; WNK1 mutants that lack an HQ domain also lack kinase activity.
The WNK1 gene encodes a cytoplasmic serine-threonine kinase expressed in the distal nephron. [5] [6] [8] Studies have shown that WNK1 can activate multiple CCCs. [5] [6] WNK1 however, does not directly phosphorylate the CCCs themselves rather it phosphorylates other serine-threonine kinases: Sterile20 related proline-alanine-rich kinase (SPAK) and oxidative stress response kinase 1 ( OXSR1). [6] [5] [7] Phosphorylation of SPAK's T loop located in its catalytic domain will activate SPAK, which will go on to phosphorylation the CCC's N-terminaldomain. [5] [6] Hence, WNK1 activates CCCs indirectly as an upstream regulator of SPAK/OSR1. [5] [6] [7]
In the distal convoluted tubule (DCT), WNK1 is a potent activator of the NCC that results in an increase in sodium re absorption that drives an increase in blood pressure. [5] [6] [7] The WNK1 mutant found in FHHt harbors a large deletion within intron 1 that causes an increase in the expression of full length WNK1. [5] [6] [7] [8] The boost in WNK1 leads to increases in NCC activation that promotes the high blood pressure/ hypertension associated with FHHt. [5] [6] [7] [8] WNK1 activates the serum-and glucocorticoid-inducible protein kinase SGK1, leading to increased expression of the epithelial sodium channel (ENaC), which also promotes sodium re absorption. [6]
WNK1 regulates potassium channels found in the cortical collecting duct (CCD) and connecting tubule (CNT). [6] Renal outer medullar potassium 1 ( ROMK1) and l arge conductance calcium-activated potassium channel (BKCa) are the two primary channels for potassium secretion. [6] WNK1 indirectly stimulates clathrin-dependent endocytosis of ROMK1 by a potential interaction with intersectin (ITSN1); thus, kinase activity is not needed. [6] Another possible mechanism of ROMK1 regulation is via autosomal recessive hypercholesterolemia (ACH), which is a clathrin adaptor molecule. [6] ACH phosphorylation by WNK1 promotes the translocation of ROMK1 to clathrin coated pits triggering endocytosis. [6] WNK1 may indirectly activate BKCa by inhibiting the actions of extracellular signal–regulated kinases (ERK1 and ERK2) that lead to lysomal degradation. [6]
The NKCC1/2 cotransporters are regulated by intracellular Cl− concentration. [9] Studies point to WNK1 as key effector that couples Cl− concentration to NKCC1/2 function. [5] [9] In hypertonic (high extracellular Cl− ) conditions that trigger cell shrinkage, an unknown mechanism upregulates WNK1 expression to counteract the volume loss. [5] The increased WNK1 leads to activation of SPAK/OSR1 that activate NKCC1/2 via subsequent phosphorylation. [5] [9] NKCC1/2 will promote the influx of Na+, K+, and Cl− ions into the cell thereby causing the flow of water into the cell. [5] In the reverse circumstances, where hypotonic (low extracellular Cl− ) conditions induce cell swelling, WNK1 is inhibited. [5] Another cotransporter, KCC is inactive when phosphorylated; without activated WNK1, KCC does not undergo phosphorylation and can activate. [5] The cotransporter will promote the efflux of K+ and Cl− ions and cause the flow of water out of the cell to combat swelling. [5]
In the mature brain, the GABA neurotransmitter represents the major inhibitory signal used in neuronal signaling. [5] GABA activates the GABAA receptor which is a Cl− ion channel. [5] Cl− ions will enter the neuron causing hyperpolarization and inhibition of signaling. [5] During brain development however, GABAA activation will allow Cl− ions to leave the neuron causing the neuron to depolarize. [5] Thus, GABA is an excitatory neurotransmitter during development. [5] WNK1 has been implicated in the developmental switch from excitatory to inhibitory GABA signaling via interaction with NKCC1 and KCCs. [5] WNK1 phosphorylates SPAK/OSR1 which then phosphorylates KCC2 inhibiting the flow of Cl− ions out of the cell during development. [5]
The concentrations of Cl− ions and K+ ion play a major role in regulating WNK1 activity. [5] [9] In the DCT, the plasma concentration of K+ ion is thought to impact the concentration Cl− ions within the nephron. [5] [9] High plasma K+ concentration down regulates WNK1 activity and prevents Cl− ion from entering the nephron via the NCC. [5] [9] The opposite occurs when plasma K+ concentration is low; increased WNK1 activity boosts NCC activity promoting reabsorption of Cl− ions. [5] [9] When there is an abundance of Cl− ions within the nephron, WNK1 activity is inhibited by the binding of a Cl− ion to WNK1's catalytic domain. [5] [9]
Furthermore, WNK1 and WNK4 may interact to form heterodimers that inhibit WNK1 function. [7] [6] WNK4 release from the heterodimer allows WNK1 monomer to bind another WNK1 monomer to promote activation. [6] [7] WNK1 function can also be inhibited if WNK1 is degraded. There are two enzymes responsible for WNK1 ubiquitination, kelch like 3 (KLHL3) and cullin 3 (CUL3). [7] [6] [10] KLHL3 serves as an adaptor protein that promotes the interaction between WNK1 and Cullin3, which is in a complex containing an E3 ubiquitin ligase that attaches the ubiquitin molecules to WNK1. [7] The ubiquitinated WNK1 will subsequently undergo proteasomal degradation. [7] [6] [10]
WNK1 has mutations associated with Gordon hyperkalemia-hypertension syndrome ( pseudohypoaldosteronism Type II, featuring hypertension also called familial hyperkalemic hypertension (FHHt) ) [5] [7] [8] and congenital sensory neuropathy ( HSAN Type II, featuring loss of perception to pain, touch, and heat due to a loss of peripheral sensory nerves). [5] [11]
The gene belongs to a group of four related protein kinases (WNK1, WNK2, WNK3, WNK4). [5] [7] [8]
Homologs of this protein have been found in Arabidopsis thaliana, C. elegans, Chlamydomonas reinhardtii and Vitis viniferaas well as in vertebrates including Danio rerio and Taeniopygia guttata. [7]
WNK1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | WNK1, HSAN2, HSN2, KDP, PPP1R167, PRKPSK, p65, WNK lysine deficient protein kinase 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 605232 MGI: 2442092 HomoloGene: 14253 GeneCards: WNK1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
WNK (lysine deficient protein kinase 1), also known as WNK1, is an enzyme that is encoded by the WNK1 gene. [5] [6] [7] [8] [9] WNK1 is serine-threonine protein kinase and part of the "with no lysine/K" kinase WNK family. [5] [6] [7] [9] The predominant role of WNK1 is the regulation of cation-Cl− cotransporters (CCCs) such as the sodium chloride cotransporter ( NCC), basolateral Na-K-Cl symporter ( NKCC1), and potassium chloride cotransporter (KCC1) located within the kidney. [5] [6] [9] CCCs mediate ion homeostasis and modulate blood pressure by transporting ions in and out of the cell. [5] WNK1 mutations as a result have been implicated in blood pressure disorders/diseases; a prime example being familial hyperkalemic hypertension (FHHt). [5] [6] [7] [8] [9]
The WNK1 protein is composed of 2382 amino acids (molecular weight 230 kDa). [8] The protein contains a kinase domain located within its short N-terminal domain and a long C-terminal tail. [8] The kinase domain has some similarity to the MEKK protein kinase family. [8] As a member of the WNK family, the kinase's catalytic lysine residue is uniquely located in beta strand 2 of the glycine loop. [8] In order to have kinase activity, WNK1 must autophosphorylate the serine 382 residue found in its activation loop. [8] [5] Further, phosphorylation at another site (Ser378) increases WNK1 activity. [5] An autoinhibitory domain is located within the C-terminal domain along with a HQ domain that is needed for WNK1 interactions with other WNKs. [5] [6] [7] [8] The interactions between WNKs play an important role in function; WNK1 mutants that lack an HQ domain also lack kinase activity.
The WNK1 gene encodes a cytoplasmic serine-threonine kinase expressed in the distal nephron. [5] [6] [8] Studies have shown that WNK1 can activate multiple CCCs. [5] [6] WNK1 however, does not directly phosphorylate the CCCs themselves rather it phosphorylates other serine-threonine kinases: Sterile20 related proline-alanine-rich kinase (SPAK) and oxidative stress response kinase 1 ( OXSR1). [6] [5] [7] Phosphorylation of SPAK's T loop located in its catalytic domain will activate SPAK, which will go on to phosphorylation the CCC's N-terminaldomain. [5] [6] Hence, WNK1 activates CCCs indirectly as an upstream regulator of SPAK/OSR1. [5] [6] [7]
In the distal convoluted tubule (DCT), WNK1 is a potent activator of the NCC that results in an increase in sodium re absorption that drives an increase in blood pressure. [5] [6] [7] The WNK1 mutant found in FHHt harbors a large deletion within intron 1 that causes an increase in the expression of full length WNK1. [5] [6] [7] [8] The boost in WNK1 leads to increases in NCC activation that promotes the high blood pressure/ hypertension associated with FHHt. [5] [6] [7] [8] WNK1 activates the serum-and glucocorticoid-inducible protein kinase SGK1, leading to increased expression of the epithelial sodium channel (ENaC), which also promotes sodium re absorption. [6]
WNK1 regulates potassium channels found in the cortical collecting duct (CCD) and connecting tubule (CNT). [6] Renal outer medullar potassium 1 ( ROMK1) and l arge conductance calcium-activated potassium channel (BKCa) are the two primary channels for potassium secretion. [6] WNK1 indirectly stimulates clathrin-dependent endocytosis of ROMK1 by a potential interaction with intersectin (ITSN1); thus, kinase activity is not needed. [6] Another possible mechanism of ROMK1 regulation is via autosomal recessive hypercholesterolemia (ACH), which is a clathrin adaptor molecule. [6] ACH phosphorylation by WNK1 promotes the translocation of ROMK1 to clathrin coated pits triggering endocytosis. [6] WNK1 may indirectly activate BKCa by inhibiting the actions of extracellular signal–regulated kinases (ERK1 and ERK2) that lead to lysomal degradation. [6]
The NKCC1/2 cotransporters are regulated by intracellular Cl− concentration. [9] Studies point to WNK1 as key effector that couples Cl− concentration to NKCC1/2 function. [5] [9] In hypertonic (high extracellular Cl− ) conditions that trigger cell shrinkage, an unknown mechanism upregulates WNK1 expression to counteract the volume loss. [5] The increased WNK1 leads to activation of SPAK/OSR1 that activate NKCC1/2 via subsequent phosphorylation. [5] [9] NKCC1/2 will promote the influx of Na+, K+, and Cl− ions into the cell thereby causing the flow of water into the cell. [5] In the reverse circumstances, where hypotonic (low extracellular Cl− ) conditions induce cell swelling, WNK1 is inhibited. [5] Another cotransporter, KCC is inactive when phosphorylated; without activated WNK1, KCC does not undergo phosphorylation and can activate. [5] The cotransporter will promote the efflux of K+ and Cl− ions and cause the flow of water out of the cell to combat swelling. [5]
In the mature brain, the GABA neurotransmitter represents the major inhibitory signal used in neuronal signaling. [5] GABA activates the GABAA receptor which is a Cl− ion channel. [5] Cl− ions will enter the neuron causing hyperpolarization and inhibition of signaling. [5] During brain development however, GABAA activation will allow Cl− ions to leave the neuron causing the neuron to depolarize. [5] Thus, GABA is an excitatory neurotransmitter during development. [5] WNK1 has been implicated in the developmental switch from excitatory to inhibitory GABA signaling via interaction with NKCC1 and KCCs. [5] WNK1 phosphorylates SPAK/OSR1 which then phosphorylates KCC2 inhibiting the flow of Cl− ions out of the cell during development. [5]
The concentrations of Cl− ions and K+ ion play a major role in regulating WNK1 activity. [5] [9] In the DCT, the plasma concentration of K+ ion is thought to impact the concentration Cl− ions within the nephron. [5] [9] High plasma K+ concentration down regulates WNK1 activity and prevents Cl− ion from entering the nephron via the NCC. [5] [9] The opposite occurs when plasma K+ concentration is low; increased WNK1 activity boosts NCC activity promoting reabsorption of Cl− ions. [5] [9] When there is an abundance of Cl− ions within the nephron, WNK1 activity is inhibited by the binding of a Cl− ion to WNK1's catalytic domain. [5] [9]
Furthermore, WNK1 and WNK4 may interact to form heterodimers that inhibit WNK1 function. [7] [6] WNK4 release from the heterodimer allows WNK1 monomer to bind another WNK1 monomer to promote activation. [6] [7] WNK1 function can also be inhibited if WNK1 is degraded. There are two enzymes responsible for WNK1 ubiquitination, kelch like 3 (KLHL3) and cullin 3 (CUL3). [7] [6] [10] KLHL3 serves as an adaptor protein that promotes the interaction between WNK1 and Cullin3, which is in a complex containing an E3 ubiquitin ligase that attaches the ubiquitin molecules to WNK1. [7] The ubiquitinated WNK1 will subsequently undergo proteasomal degradation. [7] [6] [10]
WNK1 has mutations associated with Gordon hyperkalemia-hypertension syndrome ( pseudohypoaldosteronism Type II, featuring hypertension also called familial hyperkalemic hypertension (FHHt) ) [5] [7] [8] and congenital sensory neuropathy ( HSAN Type II, featuring loss of perception to pain, touch, and heat due to a loss of peripheral sensory nerves). [5] [11]
The gene belongs to a group of four related protein kinases (WNK1, WNK2, WNK3, WNK4). [5] [7] [8]
Homologs of this protein have been found in Arabidopsis thaliana, C. elegans, Chlamydomonas reinhardtii and Vitis viniferaas well as in vertebrates including Danio rerio and Taeniopygia guttata. [7]